| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Iain Jorda. Psilocybin for Depression. The New England journal of medicine. vol 385. issue 9. 2021-09-06. PMID:34437795. |
psilocybin for depression. |
2021-09-06 |
2023-08-13 |
Not clear |
| Fredrik Hieronymus, Søren D Østergaar. Psilocybin for Depression. The New England journal of medicine. vol 385. issue 9. 2021-09-06. PMID:34437796. |
psilocybin for depression. |
2021-09-06 |
2023-08-13 |
Not clear |
| Gerhard Gründer, Lea Merten. Psilocybin for Depression. The New England journal of medicine. vol 385. issue 9. 2021-09-06. PMID:34437797. |
psilocybin for depression. |
2021-09-06 |
2023-08-13 |
Not clear |
| Robin Carhart-Harris, Allan Blemings, David J Nut. Psilocybin for Depression. Reply. The New England journal of medicine. vol 385. issue 9. 2021-09-06. PMID:34437798. |
psilocybin for depression. |
2021-09-06 |
2023-08-13 |
Not clear |
| Dominika Psiuk, Emilia Nowak, Krystian Cholewa, Urszula Łopuszańska, Marzena Samardakiewic. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life (Basel, Switzerland). vol 11. issue 8. 2021-08-31. PMID:34440508. |
a literature search of the pubmed/medline database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, mdma, dmt, or lsd for the treatment of depression symptoms. |
2021-08-31 |
2023-08-13 |
Not clear |
| Dominika Psiuk, Emilia Nowak, Krystian Cholewa, Urszula Łopuszańska, Marzena Samardakiewic. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life (Basel, Switzerland). vol 11. issue 8. 2021-08-31. PMID:34440508. |
moreover, one study revealed that psilocybin has comparable efficacy to escitalopram in the treatment of depression. |
2021-08-31 |
2023-08-13 |
Not clear |
| Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza, Piotr Gorczyca, Robert Pudl. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451890. |
lysergic acid diethylamide, psilocybin and dimethyltryptamine in depression treatment: a systematic review. |
2021-08-31 |
2023-08-13 |
Not clear |
| Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza, Piotr Gorczyca, Robert Pudl. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451890. |
the aim of this study was to evaluate the efficiency of lsd, psilocybin and dmt in depression treatment in the light of current medical literature. |
2021-08-31 |
2023-08-13 |
Not clear |
| Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza, Piotr Gorczyca, Robert Pudl. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451890. |
most of the selected studies showed significant correlation between psilocybin and dmt use and reduction in depression symptom intensity. |
2021-08-31 |
2023-08-13 |
Not clear |
| Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza, Piotr Gorczyca, Robert Pudl. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451890. |
by analyzing qualified studies, it can be concluded that psilocybin and dmt could be useful in depression treatment, but further observations are still required. |
2021-08-31 |
2023-08-13 |
Not clear |
| J R Kelly, M T Crockett, L Alexander, M Haran, A Baker, L Burke, C Brennan, V O'Kean. Psychedelic science in post-COVID-19 psychiatry. Irish journal of psychological medicine. vol 38. issue 2. 2021-06-24. PMID:32811575. |
the compass pathways (compass) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (trd) is underway to determine the safety, efficacy and optimal dose of psilocybin. |
2021-06-24 |
2023-08-13 |
Not clear |
| N L Mason, K P C Kuypers, F Müller, J Reckweg, D H Y Tse, S W Toennes, N R P W Hutten, J F A Jansen, P Stiers, A Feilding, J G Ramaeker. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 12. 2021-06-23. PMID:32446245. |
there is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. |
2021-06-23 |
2023-08-13 |
Not clear |
| Meghan Hibicke, Alexus N Landry, Hannah M Kramer, Zoe K Talman, Charles D Nichol. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. ACS chemical neuroscience. vol 11. issue 6. 2021-05-24. PMID:32133835. |
psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. |
2021-05-24 |
2023-08-13 |
human |
| Meghan Hibicke, Alexus N Landry, Hannah M Kramer, Zoe K Talman, Charles D Nichol. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. ACS chemical neuroscience. vol 11. issue 6. 2021-05-24. PMID:32133835. |
to address these questions, we tested psilocybin, lysergic acid diethylamide (lsd), and ketamine in a rat model for depression. |
2021-05-24 |
2023-08-13 |
human |
| Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffith. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA psychiatry. vol 78. issue 5. 2021-05-06. PMID:33146667. |
recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. |
2021-05-06 |
2023-08-13 |
Not clear |
| Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nut. Trial of Psilocybin versus Escitalopram for Depression. The New England journal of medicine. vol 384. issue 15. 2021-04-27. PMID:33852780. |
trial of psilocybin versus escitalopram for depression. |
2021-04-27 |
2023-08-13 |
Not clear |
| Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nut. Trial of Psilocybin versus Escitalopram for Depression. The New England journal of medicine. vol 384. issue 15. 2021-04-27. PMID:33852780. |
psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. |
2021-04-27 |
2023-08-13 |
Not clear |
| Stephen Ross, Gabrielle Agin-Liebes, Sharon Lo, Richard J Zeifman, Leila Ghazal, Julia Benville, Silvia Franco Corso, Christian Bjerre Real, Jeffrey Guss, Anthony Bossis, Sarah E Menneng. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS pharmacology & translational science. vol 4. issue 2. 2021-04-17. PMID:33860185. |
these preliminary results implicate psilocybin treatment as a potentially effective alternative to existing antidepressant medications in patients with cancer that are also suicidal, and warrant further investigation in participants with elevated levels of depression and suicidality. |
2021-04-17 |
2023-08-13 |
human |
| Jose Carlos Bouso, Genís Ona, Rafael G Dos Santos, Jaime E C Halla. Psychedelic Medicines in Major Depression: Progress and Future Challenges. Advances in experimental medicine and biology. vol 1305. 2021-04-12. PMID:33834416. |
partly because of the need of innovative treatments in psychiatry, several studies have assessed the safety and efficacy of drugs like psilocybin or ayahuasca for a wide range of mental disorders, including major depression. |
2021-04-12 |
2023-08-13 |
Not clear |
| Sara J Tai, Elizabeth M Nielson, Molly Lennard-Jones, Riikka-Liisa Johanna Ajantaival, Rachel Winzer, William A Richards, Frederick Reinholdt, Brian D Richards, Peter Gasser, Ekaterina Malievskai. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. Frontiers in psychiatry. vol 12. 2021-03-03. PMID:33643087. |
development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. |
2021-03-03 |
2023-08-13 |
Not clear |